AG
NRIX icon

Algert Global’s Nurix Therapeutics NRIX Stock Holding History

Algert Global’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-51,347
Closed -$796K – 1360
2026
Q1 		$796K Sell
51,347
-68,310
-57% -$1.13M 0.01% 902
2025
Q4 		$2.27M Sell
119,657
-444,180
-79% -$6.38M 0.04% 680
2025
Q3 		$5.21M Buy
563,837
+449,338
+392% +$4.67M 0.09% 403
2025
Q2 		$1.3M Buy
+114,499
New +$1.24M 0.03% 751
2023
Q4 		– Sell
-42,371
Closed -$333K – 1217
2023
Q3 		$333K Hold
42,371
– – 0.02% 865
2023
Q2 		$423K Buy
42,371
+2,160
+5% +$22K 0.02% 839
2023
Q1 		$357K Buy
40,211
+13,907
+53% +$145K 0.02% 902
2022
Q4 		$289K Buy
26,304
+3,710
+16% +$44.7K 0.02% 936
2022
Q3 		$294K Buy
22,594
+7,614
+51% +$121K 0.02% 952
2022
Q2 		$190K Buy
+14,980
New +$170K 0.01% 1035
2022
Q1 		– Sell
-13,053
Closed -$378K – 1269
2021
Q4 		$378K Sell
13,053
-460
-3% -$13.9K 0.05% 646
2021
Q3 		$405K Buy
+13,513
New +$417K 0.05% 632

Other funds holding NRIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Algert Global's NRIX Position: Q2 2026 in Review

Algert Global sold out of Nurix Therapeutics (NRIX) in Q2 2026, closing a stake of 51,347 shares — an estimated $796K sold.

Algert Global first reported a position in NRIX in Q3 2021 and held it in 12 quarters. The position peaked at $5.21M in Q3 2025. 212 funds tracked by Wall St. Rank hold NRIX as of Q2 2026.

  • Algert Global reported no remaining Nurix Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Algert Global sold 51,347 Nurix Therapeutics shares in Q2 2026, an estimated $796K.
  • Algert Global first reported a position in Nurix Therapeutics in Q3 2021 and held it in 12 quarters.
  • Algert Global's Nurix Therapeutics position peaked at $5.21M in Q3 2025.
  • 212 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2026.

Based on Algert Global's 13F filing for Q2 2026, filed 13 Aug 2026.